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Gene expressionMicroRNAs have tumor suppressive or oncogenic roles in carcinogenesis. This study aimed to inves-
tigate the mechanism of let-7c in suppressing lung cancer cell proliferation. First, let-7c was
revealed to be able to inhibit lung adenocarcinoma cell proliferation signiﬁcantly. TRIB2 was further
demonstrated to be a novel target and negatively regulated by let-7c. As downstream signals of
TRIB2, the activities of C/EBP-a and phosphorylated p38MAPK were increased obviously in let-7c-
treated cells compared with controls. Our results demonstrate that, through regulating the expres-
sion of TRIB2 and its downstream factors, let-7c can effectively inhibit A549 cell proliferation
in vitro and in vivo.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small, non-protein coding RNAs,
which expression correlates with biological characteristics of can-
cer, such as aggressiveness, angiogenesis, cell differentiation, inva-
sion, and metastatic behavior [1,2]. MiRNAs relevant to human
cancer are generally divided into two groups. Oncogenic miRNAs
are up-expressed in cancer and tumor suppressive miRNAs are de-
leted or down-expressed in cancer. All these miRNAs, binding to
complementary sequences of their targets (oncogenes or tumor
suppressors), suppress protein expression through their targeted
mRNAs [3].
The let-7 family functions as tumor suppressive miRNAs in a
variety of human tissues, particularly in lung tissue, bydown-expression of multiple oncogenes. For example, RAS and
MYC are targeted and negatively regulated by let-7 [4]. Both RAS
and MYC have been indicated as key oncogenes in lung cancer
and have multiple complementary sites of let-7 in their mRNA
3’-UTR. Lower expression of let-7 and higher expression of RAS
are found in lung tumor tissues, supporting that let-7 regulates
RAS expression as a mechanism for lung oncogenesis [4]. Via the
predicted binding site in c-MYC mRNA 3’-UTR, let-7 can also de-
crease oncogenic c-MYC expression. Moreover, let-7 family can
functionally inhibit cell cycle regulators like CDC25A, CDK6 and
Cyclin D2 [5], and suppress the proliferation of lung cancer cell
in vitro [4] and in vivo [6].
Let-7c, one member of let-7 family, acts as a potential tumor
suppressor in cancers. Let-7c expression is down-regulated in cas-
tration-resistant prostate cancer cells. Over-expression of let-7c
decreases cell proliferation and clonogenicity of prostate cancer
PCa cells [7]. let-7c could suppress androgen receptor (AR) expres-
sion and prostate cancer cell proliferation via a transcriptional
mechanism inhibiting Myc expression, while down-regulation of
let-7c by antisense oligonucleotides (ASO) increased AR expression
[8]. Let-7c Levels are found to be signiﬁcantly lower in hepatocel-
lular carcinoma (HCC) tissues than those in corresponding normal
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down-regulation of let-7c and poor tissue differentiation in HCC.
Apart from its tumor growth suppressive role, let-7c also functions
as a tumor metastasis suppressor in colorectal cancer by directly
destabilizing the expression of MMP11 and PBX3 [9]. However,
few studies are reported about the role of let-7c in lung cancer.
In this study, we constructed let-7c expression vector to express
let-7c effectively and investigated the mechanism of let-7c inhibit-
ing lung adenocarcinoma cell proliferation.
2. Materials and methods
2.1. Real-time PCR
MiRNAs in lung cancer tissues (from the Afﬁliated Hospital to
Binzhou Medical University after a curative operation, with ap-
proval from the Medical Ethics Committee of Binzhou Medical Uni-
versity. Written informed consent of each patient was obtained),
A549 cells or xenografts were isolated by mirVana™ miRNA Kit
(Ambion, USA) and added ploy (A) by poly (A) polymerase (Ambi-
on, USA). Then, cDNA was synthesized and real-time PCR was per-
formed to detect let-7c levels as our previous report [10]. Forward
primer is: 50-GGTTGAGGTAGTAGGTTGTATGGT-30. Reverse primer
is: 50-AACATGTACAGTCCATGGATG-30. Human 5S rRNA used as
control. All experiments were preformed in 3 triplicates.
2.2. Cell culture and transfection
A549 cell line (obtained from Chinese Academy of Sciences Cell
Bank, Shanghai, China, http://www.cellbank.org.cn) was cultured
in F12 media containing 10% fetal calf serum (Hyclone, Australian)
and 100 U/ml of penicillin-streptomycin (Sigma, USA) at 37 C
incubator with 5% CO2.
For transfection, 1  106 cells were treated with total 1 lg plas-
mid (or 0.5 lg miRNA) in 2.5 ll of lipofectamine 2000 (Invitrogen,
USA) according to the manufacturer’s instructions. All transfec-
tions were performed in 3 triplicates.
2.3. MTT assay
The modiﬁed colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was performed to inves-
tigate A549 cell proliferation as our previous studies [11,12].
2.4. Apoptosis detection
Cells were transfected with let-7c, mu-let-7c (with seed se-
quence mutation), let-7c inhibitor (ASO-let-7c, the sequences were
shown in Supplementary Table 1) or let-7c expression vector (and
control plasmid) for 48 h. The fraction of apoptotic cells was deter-
mined by propidium iodide (PI, Sigma, USA). Cells were ﬁxed in
cold 70% ethanol overnight and centrifuged 10 min at high speed
(3000 rpm). The tubes were removed to pour off ethanol. Cells
were re-suspended in residual ethanol by gently vortex. 0.5 ml PI
staining solution (50 lg/ml) was added to each tube. Then, the
mixture was incubated for 30 min and analyzed by one ﬂow
cytometry (Beckman-Coulter, Inc., USA).
2.5. Cell cycle Detection
A549 cells were harvested and washed with 1  PBS buffer.
2  106 cells were incubated in a 15 ml V-bottomed tube on ice.
Then, 3 ml cold (20 C) absolute ethanol was added to ﬁx cells
overnight. The cells were washed twice with 1  PBS and added
1 ml of propidium iodide staining solution (50 lg/ml) to cell pelletand mix well. Add 50 ll of RNase A stock solution and incubate 3 h
at 4 C. The cell cycle was analyzed by a ﬂow cytometry (Beckman-
Coulter, Inc., USA).
2.6. GFP expression analysis
Fourty-eight hours after transfection, GFP expression in A549
cells was observed under one ﬂuorescent microscope. The percent-
age of GFP-positive cells was investigated by ﬂow cytometry as fol-
lows: 2  106 cells were harvested and centrifuged for 5 min at
500 g. The cells were analyzed.
2.7. Western blot
Cells were lyzed and each 35 lg protein sample was subjected
to SDS-PAGE, transferred to polyvinylidene diﬂuoride membrane,
and immunoblotted with antibodies against TRIB2 (Santa Cruz Bio-
technology, USA), CCAAT/enhancer-binding proteins (C/EBP-a),
and mitogen-activated protein kinase (p-p38MAPK, Bioworld,
USA). The membrane was stripped and reblotted with GAPDH or
Actin antibody (1:500, Beijing Zhong Shan-Golden Bridge Technol-
ogy Co., Ltd., China) as the loading control. Secondary antibodies
conjugated to horseradish peroxidase were used for detection
and followed by enhanced chemiluminescence and
autoradiography.
2.8. A549 lung cancer xenografts
After transfection with let-7c expression vector for 48 h, the
cells were treated with trypsin, and were counted and gently
washed with PBS. Then, 1  107 cells were subcutaneously injected
into the lower back of 8 week old BALB/C-nu mice (HFK Bio-Tech-
nology Co. Ltd, China). Once the palpable tumors were developed
in mice, tumor growth was detected by caliper measurements
and the growth curve was drawn. The tumor volume was calcu-
lated using the formula: v = length width2/2 (length > width).
2.9. Statistical analysis
SAS software was used to analyze the signiﬁcance of all results.
The Student’s t-test was carried for inter-group comparison. A P-
value <0.05 is considered signiﬁcant.
3. Results
3.1. Down-expression of let-7c in lung cancer tissues and its
suppressive role in A549 cell proliferation
Previous work strongly indicated that let-7 family was tumor
suppressors in lung tissue [4]. In this study, we also found that
let-7c was down-expressed in lung adenocarcinoma tissues than
that in para-carcinoma tissue controls (Fig. 1A), supporting the
suppressive role of let-7c in lung cancer.
To further investigate the role of let-7c in the growth of lung
adenocarcinoma cells, MTT assay was performed to reﬂect the pro-
liferation of let-7c-treated A549 cells. A549 cell proliferation was
revealed to be inhibited obviously by let-7c treatment (P < 0.05),
but not changed signiﬁcantly in mu-let-7c-treated cultures
(Fig. 1B and C). In contrast to the suppressive role of let-7c, anti-
sense RNA (ASO), speciﬁc to let-7c, didn’t suppress, but increased
A549 cell proliferation to some degrees (Fig. 1B and C).
To determine whether the decrease of cell number was due to
apoptosis induced by let-7c, Annexin V-FITC apoptosis detection
was performed and observed under one ﬂuorescence microscope,
or through ﬂow cytometry as our previous study [12]. Annexin
Fig. 1. Expression of let-7c in lung cancer tissues and it regulating A549 cells growth. (A) Expression of let-7c was much lower in lung adenocarcinoma tissues compared with
para-carcinoma tissue controls (⁄P < 0.01, n = 3). (B) MTT assay showed that the inhibiting rate of A459 cell growth was increased in let-7c-treated cultures. n = 3 replicates.
(C) Fewer alive cells were found in let-7c- or let-7c-vector-treated (Plas-let-7c) cultures compared to controls (mu-let-7c or Plas-con-treated cells). Scale bar = 50 lM. (D)
FACS analysis. More apoptotic A549 cells were found in Let-7c- or let-7c-vector-treated cultures than controls (mu-let-7c or Plas-con-treated cells). n = 3 replicates. (E) Cell
cycle distribution of A549 cells transfected with let-7c, mu-let-7c, ASO-let-7c, Plas-let-7c and their controls. Negative, mock transfections. mu-let-7c, cells treated mutation
sequence of let-7c. ASO-let-7c, cells treated with antisense RNA speciﬁc to let-7c. let-7c, cells treated with let-7c oligos. Plas-con and plas-let-7c, cells treated with control and
let-7c vector, respectively. n = 3 replicates.
P.-Y. Wang et al. / FEBS Letters 587 (2013) 2675–2681 2677V-FITC is a ﬂuorescent probe which binds to phosphatidylserine
exposure in the presence of calcium. PI staining was also used to
detect the apoptotic DNA fragments. Under ﬂuorescence micro-
scope, fewer alive cells were found in let-7c-treated cultures com-
pared to mu-let-7c-treated or untreated control cells (Fig. 1D).
Flow cytometry analysis revealed that the apoptotic rate was
46.48% in let-7c-treated cells, higher cells than that in mu-let-7c-
(4.18%) or untreated control cells. Moreover, let-7c inhibitor
(ASO-let-7c) could suppress A549 cell apoptosis induced by let-
7c, supporting that the suppressive role of let-7c in lung cancer.
The above results indicated that let-7c was a tumor suppressor
miRNA, which could suppress A549 cell proliferation and induce
cell apoptosis. To further test whether the suppressive effect of
let-7c was relevant to regulating cell cycle, ﬂow cytometry analysis
was used to detect the changes of cell cycle after A549 cells were
treated with let-7c oligos. Our results demonstrated that a signiﬁ-
cant increase in the percentage of A549 cells in G0-G1 (P < 0.01;
Fig. 1E) in let-7c-treated cells compared to those in control cultures,
suggesting that the tumor suppressor role of let-7c is relevant to
regulating cell cycle, most likely due to a block in the G1-S
transition.
3.2. Construction of let-7c expression vector to inhibit cell growth
The direct transfection of chemically synthesized miRNA into
cells is one popular approach. However, the non-continuous pres-
ence of miRNA in cells renders this technique less feasible forin vivo long-term studies. Therefore, let-7c expression vector dri-
ven by U6 promoter was constructed (Supplementary methods)
to explore the application of let-7c in lung cancer therapy. We
found that the A549 cell proliferation was inhibited signiﬁcantly
(Fig. 1B and Fig. 2) and more apoptotic cells were found in let-
7c-vector-treated cells compared to that in control plasmid (Plas-
con)-treated cultures (Fig. 2), indicating that let-7c expression vec-
tor could express let-7c to inhibit A549 cell growth effectively.
To investigate the targeting genes of let-7c, the relationship be-
tween let-7c and its targets was predicted online using microRNA
TargetScan software (http://www.targetscan.org/index.html) and
microRNA.org (http://www.microrna.org/microrna/getGeneForm.
do). These sites provide a comprehensive analysis of the targeting
gene of miRNA, which demonstrated that 3’-UTR of TRIB2 was tar-
geted by let-7c (Fig. 3A). Therefore, we focused on TRIB2 gene,
which was reported as one oncogene in lung tumorigenesis re-
cently [11,13]. Our results further proved that TRIB2 expression
in lung carcinoma was higher than that in para-carcinoma tissue
controls (Suppl. Fig. 1). Then, pcDNA-GFP-TRIB2-3’UTR vector, con-
tained 3’-UTR of TRIB2 downstream of the GFP gene, was con-
structed as our previous study [10] to analyze the role of let-7c
in regulating TRB2 expression. After A549 cells treated with
pcDNA-GFP-TRIB2-3’UTR plasmid with let-7c, the GFP expression
was estimated by the examination of ﬂuorescence microscopy
and ﬂow cytometry. The intensity of ﬂuorescence in let-7c-tran-
fected cells was decreased obviously than that in mu-let-7c- or
ASO-let-7c-treated cultures (Fig. 3B). The percentage of positive
Fig. 2. Structure of let-7c expression vector and its inhibition to cell proliferation. (A) Structure of let-7c expression vector. U6 promoter is used to drive let-7c expression. (B)
Real-time PCR revealed that let-7c was over-expressed in let-7c-vector-treated A549 cells than its control plasmid-treated cultures. n = 3 replicates. (C) MTT assay showed
that the inhibiting rate to A459 cell was higher in let-7c-vector-treated A549 cultures than controls. n = 3 replicates.
Fig. 3. TRIB2 3’-UTR was regulated by let-7c. (A) This ﬁgure showed that the site of TRIB2 3’-UTR is targeted by let-7c. (B) Scale bar = 100 lM. The number of GFP positive cells
and intensity of GFP ﬂuorescence in let-7c-treated cultures were decreased obviously compared with control cultures under a ﬂuorescence microscopy. n = 3 replicates. (C)
FACS results showed that the ratio of GFP positive cells in let-7c-treated cultures was much lower than that in controls. n = 3 replicates.
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in mu-let-7c- (57.76%) or ASO-let-7c-treated controls (51.34%)
(Fig. 3C), indicating that TRIB2-3’UTR was targeted and regulated
by let-7c.
To further prove the role of let-7c in regulating protein expres-
sion of TRIB2, we constructed pcDNA-TRIB2 vector to over-express
TRIB2 protein as positive control. SiRNA speciﬁc to TRIB2 was also
designed to inhibit TRIB2 expression obviously as a control (Suppl.
Fig. 2). Then, we measured the levels of TRIB2 in A549 cells using
western blot after let-7c or its expression vector treatment. Our re-
sults revealed that TRIB2 expression decreased more than 3 folds
in let-7c- (or its expression-vector)-treated cells compared to con-
trol cultures (Fig. 4A and B). Thus, as a strong upstream factor, let-
7c could regulate cell growth by inhibiting oncogenic TRIB2
expression.
3.3. Let-7c vector regulating the expression of C/EBPa or p-38MAPK
In the previous studies, C/EBPa was shown to be a downstream
factor of TRIB2 [14]. Therefore, we investigated whether C/EBPa
expression was regulated by let-7c. Our results revealed that afterlet-7c inhibiting TRIB2 expression, C/EBPawas increased obviously
in let-7c-vector-treated cells than that in controls (Fig. 4C and D).
The regulation of C/EBPa expression by let-7c was further proved
using pcDNA-TRIB2 vector and siRNA vector (Fig. 4A-D), support-
ing that Let-7c could regulate the expression of C/EBPa through
TRIB2.
Activation of the phosphorylation of mitogen-activated protein
kinase (MAPK) is related to anticancer therapy [14,15], and TRIBs
can bind to MAPKK and regulate MAPK activation [16]. To further
investigate the affect of let-7c and TRIB2 on MAPK activities, the
expression phosphorylation of p38MAPK (p-p38MAPK) was as-
sessed after A549 cells were treated with Let-7c expression vector.
Our results showed that p-p38MAPK was increased in let-7c-vec-
tor-treated cells than that in controls (Fig. 4E-G), which indicates
that let-7c may suppress cell growth by regulating MAPK activities.
3.4. Suppressing A549 cell growth in node mice by let-7c vector
The above results show that let-7c, as tumor suppressor gene, is
potentially useful miRNA for tumor therapy. Therefore, we ob-
served the application of let-7c to suppress A549 cell growth
Fig. 4. Western blot analysis. (A) Detection of TRIB2 expression. TRIB2 expression was reduced signiﬁcantly in let-7c- and let-7c-vector-treated A549 cells, respectively, than
that in controls. TRIB2 was over-expressed in pcDNA-TRIB2-vector-treated cells than controls. (B) Relative values for TRIB2 vs GAPDH of Fig. 5A. ⁄P < 0.05 vs negative control.
#P < 0.01 vs Plas-con control. n = 3 replicates. (C) C/EBPa expression was increased obviously in let-7c- and let-7c-vector- treated A549 cells, while decreased in pcDNA-
TRIB2-vector-treated cells. (D) Relative values for TRIB2 vs GAPDH of Fig. 5C. ⁄P < 0.01 vs negative control. #P < 0.01 vs Plas-con control. (E) p-p38MAPK expression was
increased obviously in let-7c-vector-treated A549 cells than that in controls, while p38MAPK was almost similar in different treatment cells. n = 3 replicates. (F) Relative
values for TRIB2 vs Actin of Fig. 5E. ⁄P < 0.01 vs negative control. (G) p-p38MAPK vs p38MAPK of Fig. 5E. ⁄P < 0.01 vs negative control. n = 3 replicates.
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back of nude mice after let-7c expression vector treatment. Tumor
volumes were calculated when the mice developed palpable tu-
mors. Our results demonstrated that tumor weights of A549 cell
xenografts turned lighter and tumor volumes became smaller in
let-7c-vector-treated mice compared with those in controls during
two-week detection (Fig. 5A and B). The expression of let-7c in the
tumor was increased obviously, while TRIB2 expression was re-
duced signiﬁcantly in let-7c-vector-treated mice than those in con-
trols (Fig. 5C–E), which indicated that let-7c vector could suppress
A549 cell growth effectively in vivo by suppressing oncogenic
TRIB2.
4. Discussion
Several therapeutic approaches of miRNAs have been proposed
for cancer therapy, e.g. inhibition of oncogenic miRNA expression;
restoration of a deactivated tumor-suppressive miRNA; or inhibi-
tion or cleavage of an oncogenic mRNA by a therapeutic miRNA
[17]. Importing/restoring a tumor suppressive miRNA to suppress
an oncogenic mRNA expression in cancer cells was considered an-
other effective way for cancer therapy [18,19]. miR-125b was
showed to inhibit VE-cadherin expression in tumor cell and to in-
duce non-functional blood vessel formation, resulting in inhibition
of tumor growth [20]. Similarly, we used U6 promoter to drive let-
7c transcription, and found that let-7c expression vector could ex-
press let-7c to further inhibit A549 cell proliferation in vitro and
in vivo effectively. Using U6 promoter to drive miRNA transcriptionwas also reported in other studies [21,22], which showed that the
Pol III promoter could yield a high expression of artiﬁcial miRNA
with a limited ﬂanking sequence.
A novel ﬁnding in this study is that let-7c could regulate onco-
genic TRIB2 expression in lung adenocarcinoma cells. As a tribbles
orthologues, trib2was ﬁrst proven to be an essential protein during
Xenopus eye and nervous system development and identiﬁed as an
autoantigen in autoimmune uveitis [23]. Keeshan et al. [11] re-
ported that trib2 was an oncogene, inducing acute myelocytic leu-
kemia in the chimeric mice bearing TIRB2-transduced bone
marrow. Similarly, our results demonstrated that trib2 was over-
expressed in the adenocarcinoma tissue and exerted its oncogenic
role in tumorigenesis through downregulating of C/EBPa.
C/EBPs reported to be functionally and physically interacting
with Tribbles proteins. C/EBPa belongs to this large family and
functions as a transcription factor in the absence of TRIB2 [24].
The transcriptional activity could be lost when TRIB2 is present
and bound to C/EBPa [13]. Over-expression of TRIB-2 induced
AML in mice possibly via enhancing degradation of certain C/EBP
proteins [25]. Loss of C/EBPa function is associated with myeloid
transformation in a variety of murine models and human leukemia
[26]. Similarly, our results demonstrated that C/EBPa expression
was increased in A549 cells when let-7c down-regulated TRIB2
expression, showing that C/EBPa, as one transcription factor, was
regulated by TRIB2.
The central element in each MAPK pathway includes three
sets of effective protein kinases, ERKs, JNKs and p38s [27]. Some
anti-tumor agents can inhibit cancer cells by the activation of
Fig. 5. A549 lung cancer xenografts were inhibited by let-7c vector. (A) The weight of tumor was smaller in let-7c-vector-treated xenografts than Plas-con-treated controls
(⁄P < 0.05, n = 5). (B) Growth curve was drawn from measurement taken 7 days after xenograft (n = 4 each group). The growth of A549 cell xenografts was inhibited by let-7c-
vector compared with the Plas-con-treated tumors. (C) Real-time PCR revealed that let-7c was up-regulated in let-7c-vector-treated tumors than controls. (D) Western blot
showed that TRIB2 expression was reduced obviously in let-7c-vector-treated A549 cells than that in controls. (E) Relative values for TRIB2 vs Actin of Fig. 6D. ⁄P < 0.01 vs
Plas-con treatment.
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anti-tumor agent, could also exert its suppressing action to inhi-
bit A549 cell growth by activation of p38MAPK. Different from
the role of TRIB2 in inﬂammatory to decrease the TLR5 ligand-
induced phosphorylation of p38 MAPK [29], we found that let-
7c could up-regulated phosphorylation of p38MAPK in lung can-
cer A549 cells through negatively regulating oncogenic TRIB2.
The roles of TRIB2 and p38MAPK in inﬂammatory or cancer need
further studied.
In summary, we used U6 promoter to drive let-7c expression
effectively in constructed let-7c expression vector, and found that
let-7c could inhibit A549 cell proliferation and induce cell apopto-
sis through down-expression of oncogenic TRIB2 and up-expres-
sion of C/EBPa (or p38-MAPK). Our results indicate that let-7c is
a valuable and potential candidate for lung cancer therapy.
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